Industrias
Biopharmaceuticals & Rare Diseases
Todos los análisis de Biopharmaceuticals & Rare Diseases — 3 análisis.
38/100
Rocket Pharmaceuticals: Cash Buys Time, but Danon Still Has to Earn Back the Market's Trust
Rocket Pharmaceuticals (RCKT.US) is a rare-disease gene-therapy developer whose sole approved product, Kresladi, still generates no revenue, leaving cash and a $180 million voucher sale as the real near-term story. The stock trades near the value of its cash alone because the market still distrusts the pivotal Danon cardiac program after a 2025 clinical hold, even though Phase 1 data and a modified lower-dose cohort keep the thesis alive. Rating Hold: cash buys time, but Danon still has to earn back trust and Kresladi is too small to carry the valuation on its own.
45/100
BioMarin Pharmaceutical: A Rare-Disease Cash Engine in Transition
BioMarin is a profitable rare-disease biopharma whose enzyme franchise generated about 2.106 billion USD of 2025 revenue and funds the company, while VOXZOGO (926.9 million USD) drives both growth and sentiment. The Amicus acquisition diversified the portfolio into Fabry and Pompe disease and lifted 2026 revenue guidance to 3.825-3.925 billion USD, yet weekly and oral achondroplasia rivals from Ascendis and BridgeBio keep the margin of safety thin. Rating Hold: cash generation and Amicus diversification make BioMarin sturdier than sentiment implies, but VOXZOGO competition caps the upside at today's price.
55/100
38Buffett
argenx (ARGX.US / ARGX.BR): un informe Zen Horizon
argenx es el líder mundial en terapias con anticuerpos para enfermedades autoinmunes raras y el pionero first-in-class del campo de los inhibidores de FcRn. Su producto central Vyvgart (efgartigimod) está aprobado ya en tres indicaciones (gMG y CIDP a escala global, más ITP en Japón), con unos 19000 pacientes en tratamiento, ventas netas de USD 4.15 mil millones en el ejercicio 2025 (+90%) y un primer beneficio operativo positivo de USD 1.05 mil millones. Vision 2030 apunta a 50000 pacientes, 10 indicaciones aprobadas y 5 moléculas en fase III. Calificación Vigilar: un activo genuinamente sólido cuyo precio de USD 882.41 ya descuenta una ejecución impecable, de modo que la ventana de entrada solo se abre con un retroceso hasta USD 720 o por debajo.